AXL and non-small cell lung carcinoma: For example, AXL kinase is associated with mesenchymal features in NSCLC and has been identified as a target to overcome EGFRi resistance,24 and in cancer models of acquired resistance to erlotinib (EGFRi), upregulation of AXL correlates with the emergence of EMT features, which has been shown to underlie erlotinib resistance.